CH BIOTECH SER (08037) announces a positive profit forecast, expecting a net profit of no less than HKD 15 million for the first half of the year.

CH BIOTECH SER (08037) announced that the group is expected to achieve a net profit of no less than HKD 15 million for the six months ending June 30, 2026, compared to a net loss of approximately HKD 37 million for the six months ending June 30, 2025. The change from a net loss to a net profit is primarily attributed to non-cash and unrealized fair value gains on convertible bonds, which may range between HKD 77 million and HKD 87 million, offset by the following items: (i) an increase in financing costs of approximately HKD 9 million due to the issuance of convertible bonds with a principal amount of USD 35 million in February 2026; (ii) approximately HKD 14 million in non-recurring compensation income not generated from insurance claims (which was recognized as other income in the same period in 2025).